Knowledge

AI-driven real-time tissue impedance monitoring integrates machine learning into electrosurgical generators to provide instantaneous alerts and automatic power adjustments. By analyzing biological signals thousands of times per second, these systems prevent thermal injury, ensuring surgical precision. This technology represents a critical leap in patient safety, allowing surgeons to operate with increased confidence and a significantly […]

Medtronic received U.S. FDA clearance for the Stealth AXiS™ Surgical System in February 2026 for spine procedures, with expansions to cranial and ENT in March 2026. This AiBLE™ smart ecosystem integrates AI-driven planning, real-time navigation, robotics, and energy delivery for precise spine and neurosurgeries. It signals a shift to connected, AI-guided workflows. For Sale COVIDIEN

The global vessel sealing market is projected to reach $2.24 billion in 2026, with electro-thermal devices like the ForceTriad maintaining the largest market share due to their efficiency in both open and laparoscopic surgeries. These devices dominate hospital procurement, driven by rising minimally invasive procedure demands and technological advancements. For Sale COVIDIEN Valleylab force Triad

Sustainability regulations in 2026 are pushing hospitals to rethink how they handle electrosurgical instruments, especially specialized single‑use devices used with platforms such as the ForceTriad. “Sustainability and Single‑Use Instrument Recycling” is no longer just about compliance—it now shapes purchasing decisions, operating‑room workflows, and the total cost of ownership. By integrating reprocessing and circular‑economy principles into

The FDA clearance of the Cala kIQ Plus, announced on April 15, 2026, authorizes this next‑generation wearable neurostimulation system for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD). Building on the company’s TAPS® technology, the Cala kIQ Plus introduces Adaptive Calibration and new therapy modes to personalize electrical stimulation, giving patients greater

The kIQ device, originally for Essential Tremor, is expanding into Parkinson’s Disease (PD) with early 2026 clinical data, including American Academy of Neurology presentations, showing effectiveness for PD hand tremors. This wearable neuromodulation tool now addresses multiple movement disorders using the same hardware. Cala KIQ Tremor Relief Therapy | Non-Invasive Wearable Device What Is kIQ

In the first half of 2026, Cala shifted its kIQ device to a connected health model, allowing secure sharing of tremor data via the MyCala portal with physicians for real-time remote monitoring of treatment progress and tremor severity. This integration turns kIQ into a diagnostic platform, enhancing value for doctors tracking therapy efficacy. Cala KIQ

The essential tremor treatment market is undergoing a profound transformation, with projections for 2026 highlighting a shift toward non-invasive wearable neuromodulation, such as the Cala kIQ. As patients increasingly favor drug-free alternatives over traditional pharmacological interventions, the market is poised to reach $210 million this year, positioning innovative wearable technologies as the new leaders in

Cala Health’s $50 million growth capital raise from Trinity Capital signals strong market confidence in its Cala kIQ system. The funding supports commercial expansion, product innovation, and long-term device support. It ensures broader availability, continued software updates, and improved patient outcomes while strengthening the company’s position in the neuromodulation market. Cala KIQ Tremor Relief Therapy

The global wearable tremor therapy market has reached approximately $874.72 million in 2026. This significant growth is primarily driven by an aging global population, the increasing prevalence of neurological disorders like Parkinson’s disease and essential tremor, and a fundamental shift toward patient-centered, at-home medical care enabled by advanced, non-invasive wearable technology and digital health integration.